Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9816857 | 0.83 | MEN1 (0.33) | ALOX12 | |
| SCHEMBL9844846 | 0.78 | — | — | |
| SCHEMBL11148616 | 0.78 | — | — | |
| SCHEMBL4661697 | 0.78 | — | — | |
| SCHEMBL6449318 | 0.78 | — | — | |
| SCHEMBL972024 | 0.78 | — | — | |
| SCHEMBL8595516 | 0.78 | — | — | |
| SCHEMBL725697 | 0.78 | — | — | |
| SCHEMBL11807036 | 0.76 | CYP3A4 (0.45) | — | |
| Fluoride Ion SCHEMBL11601744 | 0.76 | TSHR (0.45) | CYP2A6ALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7208139-B2 | Conducting nuclear spin tomography on a patient who has been administered a cascade polymer complex having complex-forming ligands for imaging of inflammation and/or tumors in the brain | SCHERING AG (DE) | 2007-04-24 | — | — | US | disclosed |
| US-20050118105-A1 | Conducting nuclear spin tomography on a patient who has been administered a cascade polymer complex having complex-forming ligands for imaging of inflammation and/or tumors in the brain | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-06-02 | — | — | US | disclosed |
| US-6855309-B2 | For use in diagnostics and therapy | SCHERING, AG (DE) | 2005-02-15 | — | — | US | disclosed |
| US-20030232017-A1 | For use in diagnostics and therapy | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2003-12-18 | — | — | US | disclosed |
| US-6576222-B2 | Complex stability and specificity; NMR contrast media as diagnostic aid for localization of vascular disease | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-06-10 | — | — | US | disclosed |
| US-20020068037-A1 | Complex stability and specificity; NMR contrast media as diagnostic aid for localization of vascular disease | SCHERING AG (DE) | 2002-06-06 | — | — | US | disclosed |
| US-6299859-B1 | ADMINISTERING CONTRAST AGENT COMPRISING CASCADE POLYMER COMPLEX AND NUCLEAR MAGNETIC RESONANCE IMAGING TISSUES FOR DIFFERENTIATING ISCHEMIC AND/OR INFRACTED TISSUE FROM NORMAL TISSUES | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-10-09 | — | — | US | disclosed |
| US-6193950-B1 | FOR DIAGNOSIS AND THERAPY | SCHERING AG (DE) | 2001-02-27 | — | — | US | disclosed |
| US-6183724-B1 | ADMINISTERING A CONTRAST AGENT FOR NMR IMAGING THE BLOOD VESSELS, SIZE LARGE ENOUGH FOR ITS RETENTION IN THE BLOOD VESSELS AND SMALL ENOUGH FOR ITS EXCRETION | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-02-06 | — | — | US | disclosed |
| US-6054117-A | NUCLEAR MAGNETIC RESONANCE CONTRAST MEDIA FOR DIAGNOSTICS AND THERAPY; PHYSIOLOGICALLY ACCEPTABLE EXCRETION | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-04-25 | — | — | US | disclosed |
| EP-0357622-A1 | SUBSTITUTED COMPLEX-FORMING SUBSTANCES, COMPLEXES AND COMPLEX SALTS, PROCESS FOR MANUFACTURE THEREOF AND PHARMACEUTICAL AGENTS WHICH CONTAIN THEM | SCHERING AKTIENGESELLSCHAFT (DE) | 1990-03-14 | — | — | EP | disclosed |
| EP-0355097-A1 | SUBSTITUTED CYCLIC COMPLEX-FORMING SUBSTANCES, COMPLEXES AND COMPLEX SALTS, PROCESS FOR MANUFACTURING SAME, AND PHARMACEUTICAL AGENTS WHICH CONTAIN THEM | SCHERING AKTIENGESELLSCHAFT (DE) | 1990-02-28 | — | — | EP | disclosed |
| EP-0331616-A2 | Polymer-bonded complexe builders, their complexes, process for their preparation and pharmaceutical agents containing the same | SCHERING AKTIENGESELLSCHAFT (DE) | 1989-09-06 | — | — | EP | disclosed |
| EP-0305320-A2 | Multinucleic substituted complexants, complexes and complex salts, process for their preparation and pharmaceutical agents containing them | SCHERING AKTIENGESELLSCHAFT (DE) | 1989-03-01 | — | — | EP | disclosed |
| WO-1988008422-A1 | SUBSTITUTED CYCLIC COMPLEX-FORMING SUBSTANCES, COMPLEXES AND COMPLEX SALTS, PROCESS FOR MANUFACTURING SAME, AND PHARMACEUTICAL AGENTS WHICH CONTAIN THEM | SCHERING AKTIENGESELLSCHAFT (DE) | 1988-11-03 | — | — | WO | disclosed |
| WO-1988007521-A1 | SUBSTITUTED COMPLEX-FORMING SUBSTANCES, COMPLEXES AND COMPLEX SALTS, PROCESS FOR MANUFACTURE THEREOF AND PHARMACEUTICAL AGENTS WHICH CONTAIN THEM | SCHERING AKTIENGESELLSCHAFT (DE) | 1988-10-06 | — | — | WO | disclosed |
| EP-0277088-A2 | Polymer complexes, process for their preparation and pharmaceutical compounds containing them | SCHERING AKTIENGESELLSCHAFT (DE) | 1988-08-03 | — | — | EP | disclosed |
| EP-0255471-A1 | 1,4,7,10-Tetraazacyclododecane-derivatives | SCHERING AKTIENGESELLSCHAFT (DE) | 1988-02-03 | — | — | EP | disclosed |
| EP-0250358-A2 | Novel complex compounds | SCHERING AKTIENGESELLSCHAFT (DE) | 1987-12-23 | — | — | EP | disclosed |
| US-3966397-A | Dyeing keratinous fibers | LEVER BROTHERS COMPANY (US) | 1976-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068037-A1 | Complex stability and specificity; NMR contrast media as diagnostic aid for localization of vascular disease | CAD, APOB, SLC7A1 | CYP2A6 4844/4885ALOX12 1563/4885 |
| US-20030232017-A1 | For use in diagnostics and therapy | TFPI, BCAT2, OAT | CYP2A6 4677/4885ALOX12 3737/4885 |
| US-20050118105-A1 | Conducting nuclear spin tomography on a patient who has been administered a cascade polymer complex having complex-forming ligands for imaging of inflammation and/or tumors in the brain | FABP7, SLC1A3, SLC43A1 | CYP2A6 4696/4885ALOX12 1976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.